Leukemia/BMT Chemotherapy Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference.Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibly of the prescribing clinician and is subject to the HSE.ie terms of use.

Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.

Leukemia/BMT Chemotherapy Regimens

Regimen Name Indication

BEAM Autologous Transplant Conditioning Protocol

Regimen

00408a

Autologous conditioning in non-Hodgkins Lymphoma (NHL)

00408b

Autologous conditioning in Hodgkins Lymphoma

Bosutinib Monotherapy

Regimen

00224a

Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

High Dose Cytarabine Therapy

Regimen

00365a

Consolidation chemotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML)

Intermediate Dose Cytarabine Therapy

Regimen

00364a

Consolidation chemotherapy for the treatment of patients Acute Myeloid Leukaemia (AML)

DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)

Regimen

00359a

Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)

DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)

Regimen 

00360a

Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)

Decitabine Monotherapy – AML (28 day cycle)

Regimen

00231a

Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy.

Fludarabine, Cyclophosamide and Rituximab ( FC (IV) + R) Therapy

Regimen

00241a

Treatment of B-cell chronic lymphocytic leukaemia (CLL).

Fludarabine, Cyclophosamide and Rituximab ( FC (Oral) + R) Therapy

Regimen

00410a

Treatment of B-cell chronic lymphocytic leukaemia (CLL).

Ibrutinib Therapy CLL/Walden Waldenström’s macroglobulinaemia

Regimen

00296a

As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.

00296b

As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.

00296c

As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

Idelalisib Monotherapy

Regimen

00291a

Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.

Idelalisib and RiTUXimab Therapy

Regimen

In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

00389a

who have received at least one prior therapy

or

00389b

as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

Idelalisib and Ofatumumab Therapy

Regimen

In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):

00390a

who have received at least one prior therapy

or

00390b

as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.

Obinutuzumab and Chlorambucil Therapy

Regimen

00286a

Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.

Ponatinib Therapy

Regimen

00302a

Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

00302b

Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.

Ruxolitinib Monotherapy

Regimen

The treatment of disease-related splenomegaly or symptoms in adult patients with:

00229a

Primary myelofibrosis (chronic idiopathic myelofibrosis)

00229b

Post polycythaemia vera myelofibrosis

00229c

Post essential thrombocythaemia myelofibrosis

Tretinoin (ATRA) /Idarubicin (PETHEMA  AIDA) Induction Therapy

Regimen

00366a

Treatment of patients with newly diagnosed Acute Promyelocytic Leukaemia (APL)